Evidence map›Paper›PMID 40956087›Full record

ReviewEpilepsia open2025

Status epilepticus: Updates on mechanisms and treatments.

Suchitra Joshi, Jaideep Kapur

Abstract readReview
In one paragraph

Review in Epilepsia open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Suchitra JoshiDepartment of Neurology, University of Virginia, Charlottesville, Virginia, USA.ORCID https://orcid.org/0000-0003-3524-2061
Jaideep KapurDepartment of Neurology, University of Virginia, Charlottesville, Virginia, USA.ORCID https://orcid.org/0000-0002-8608-1352

Funding

Ketamine Add-On for Established Status Epilepticus Treatment Trial (KESETT)UG3NS131532 · NINDS · UNIVERSITY OF VIRGINIA · PI CHAMBERLAIN, JAMES, KAPUR, JAIDEEP · 2025 to 2025
$9.3M
Secondarily generalized tonic clonic seizure; a functional anatomyR37NS119012 · NINDS · UNIVERSITY OF VIRGINIA · PI Jaideep Kapur · 2021 to 2026
$3.4M
Motor cortex plasticity in temporal lobe epilepsyR01NS120945 · NINDS · UNIVERSITY OF VIRGINIA · PI KAPUR, JAIDEEP · 2021 to 2025
$2.5M
Progesterone receptor regulation of seizuresR01NS110863 · NINDS · UNIVERSITY OF VIRGINIA · PI JOSHI, SUCHITRA · 2019 to 2023
$1.8M
Progesterone receptors and migraine chronificationR21NS140790 · NINDS · UNIVERSITY OF VIRGINIA · PI JOSHI, SUCHITRA · 2025 to 2025
$444k
NINDS NIH HHS NS 110863NINDS NIH HHS NS 140790-01A1NINDS NIH HHS R01 NS110863NINDS NIH HHS R01 NS120945NINDS NIH HHS R21 NS140790NINDS NIH HHS R37 NS119012NINDS NIH HHS UG3 NS131532NINDS NIH HHS UG3NS131532
6 · The paper itself

Abstract

Status epilepticus (SE) consists of prolonged, self-sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super-refractory SE. Studies in experimental animals have found impaired GABAergic inhibition and potentiated glutamatergic neurotransmission in SE animals. These alterations increase the number of active neurons and expand the seizure network. Here, we first discuss the changes in GABA-A, NMDA, and AMPA receptor-mediated synaptic transmission during SE and elaborate on emerging studies showing the neuronal consumption of alternate energy sources to cope with increased energy demand. Then, we discuss the clinical studies that have tested the efficacy of various benzodiazepines and other anticonvulsant agents in treating SE in prehospital and in-hospital settings. Finally, we briefly summarize the ongoing clinical studies and the potential for other anticonvulsant agents to be tested for treating SE. PLAIN LANGUAGE SUMMARY: Most seizures are self-limiting, but some seizures change the brain such that a constant state of seizures, SE, is generated. These prolonged seizures can cause neuronal injury and increase the risk of death. We discuss the molecular mechanisms that sustain these seizures and the accompanying neuronal and network plasticity. We also review the current SE treatment and future directions.

Indexed as

benzodiazepinescalcium‐permeable AMPA receptorsGABA‐A receptorsNMDA receptorsreceptor trafficking

Identifiers

PMID40956087
PMCPMC13394038

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.